葡萄糖类-1受体激活剂与2型糖尿病老年人癌症风险的关联
Ying Lu1, Hao Dai2, Huilin Tang1,3
1Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
Obesity (Silver Spring, Md.)
|August 21, 2025
概括
在2型糖尿病患者中,葡萄糖类-1受体激动剂 (GLP-1RA) 可能会增加和子宫内膜癌的风险. 需要进一步的研究来证实这些发现,并评估潜在的致风险.
科学领域:
- 内分泌学
- 癌症学
- 药物监督管理
背景情况:
- 关于GLP-1RA与癌症风险的相关证据有限.
- 现有研究对GLP-1RAs与癌症发展有关的安全性概况提出了不同的结论.
研究的目的:
- 研究GLP-1RAs与9种与肥胖相关的癌症的风险之间的联系.
- 将GLP- 1RAs与SGLT2抑制剂或DPP4抑制剂的癌症风险进行比较.
主要方法:
- 使用了2013-2020年国家医疗保险要求的2型糖尿病癌症患者数据.
- 使用1:1的倾向性匹配来比较GLP-1RA启动器与SGLT2i和DPP4i启动器.
- 应用考克斯的比例危险模型来估计各种癌症的危险比率.
主要成果:
- 与SGLT2抑制剂相比,GLP- 1RA使用与癌的风险显著增加有关 (HR,1. 43 [1. 06-1.92]).
- 与DPP4抑制剂相比,GLP- 1RA使用与子宫内膜癌的风险显著增加有关 (HR,1. 55 [1. 01-2.37]).
- 在GLP- 1RA和SGLT2i或DPP4i使用者之间没有观察到总体癌症风险的显著差异.
结论:
- GLP-1RA可能与特定类型的癌症,特别是脏和子宫内膜癌的风险增加有关.
- 需要进一步的研究来验证与GLP-1RA相关的潜在瘤性风险.
相关概念视频
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Oral Hypoglycemic Agents: Biguanides and Glitazones
291
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
291
Hypoglycemia and Glucagon
334
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
334
Oral Hypoglycemic Agents: Glinides
257
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
257
Psychoneuroimmunology: Diabetes and Cancer
62
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
62
Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256


